Clinical Trial Update: Maraviroc as GVHD Prophylaxis in Transplant Recipients [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports termination of a study evaluating maraviroc for GVHD prophylaxis in transplant recipients, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Stem Cell Transplantation

Drugs mentioned

• Maraviroc (maraviroc)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Diagnoses That Require Stem Cell Transplant, Graft Versus Host Disease (GVHD) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-03-10